Monthly Archives: September 2013

Sixth Annual Chair Summit Begins This Week

This week a Master Class for Neuroscience Development called the Chair Summit takes place in Tampa, FL (Sept 26-28, 2013). In the early days of medical training in Kos, students, trainees and medical colleagues would gather to discuss their cases … Continue reading

Posted in Addiction, ADHD, Antipsychotic medication, Anxiety Disorders, Biomarker, Bipolar Disorder, Cardiovascular Risk Factors, Chronic Pain, CME, Dementia, Depression, Diabetes, Diagnosis, Digital medicine, Drug Development, Drugs, DSM-5, Early intervention, Education, Food, Genetics, Guideline, Imaging, Maintenance of Certification, Measurement-based care, Medical Education, Mood, MRI, Multiple sclerosis, Negative symptoms, Neuroscience, Obesity, Opioids, PET, Practice guideline, Psychosis, PTSD, Research, Schizophrenia, Smoking cessation, Social media, Stroke, Substance abuse, Transcranial magnetic stimulation, Vascular dementia | Comments Off on Sixth Annual Chair Summit Begins This Week

FDA Modifies Label for ER/LA Opioids

The Food and Drug Administration yesterday announced changes to the labeling requirements for long-acting pain medication. In addition, FDA has ordered new postmarket study requirements for all extended-release and long-acting (ER/LA) opioid analgesics intended to treat pain. The modified indication, … Continue reading

Posted in Uncategorized | Comments Off on FDA Modifies Label for ER/LA Opioids